Literature DB >> 18027163

Phenotypes of chronic obstructive pulmonary disease.

Adam L Friedlander1, David Lynch, Liesel A Dyar, Russell P Bowler.   

Abstract

The current clinical classification of smoking-related lung disease fails to take into account the heterogeneity of chronic obstructive pulmonary disease (COPD). With an increased understanding of pathophysiologic variation, COPD now clearly represents a spectrum of overlapping diseases with important extrapulmonary consequences. A "phenotype" describes the outward physical manifestations of a particular disease, and compromises anything that is part of the observable structure, function or behavior of an individual. Such phenotypic distinctions in COPD include: frequent exacerbator, pulmonary cachectic, rapid decliner, airways hyperresponsiveness, impaired exercise tolerance, and emphysema versus airways disease. These variable manifestations, each with unique prognostic, clinical and physiologic ramifications, represent distinct phenotypes within COPD. While all of these phenotypes have smoking as a common risk factor, the other risk factors that determine these phenotypes remain poorly understood. An individual smoker has variable expression of each phenotype and there is mounting evidence that COPD phenotypes have different clinical outcomes. These phenotypes can be broadly classified into one of three groups: clinical, physiologic and radiographic. This review presents the evidence for the spectrum of COPD phenotypes with a focused discussion on the pathophysiologic, epidemiologic and clinical significance of each subtype.

Entities:  

Mesh:

Year:  2007        PMID: 18027163     DOI: 10.1080/15412550701629663

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  48 in total

1.  Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies.

Authors:  Motoi Hosoe; Ralph Woessner; Soichiro Matsushima; David Lawrence; Benjamin Kramer
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Relationships between airflow obstruction and quantitative CT measurements of emphysema, air trapping, and airways in subjects with and without chronic obstructive pulmonary disease.

Authors:  Joyce D Schroeder; Alexander S McKenzie; Jordan A Zach; Carla G Wilson; Douglas Curran-Everett; Douglas S Stinson; John D Newell; David A Lynch
Journal:  AJR Am J Roentgenol       Date:  2013-09       Impact factor: 3.959

3.  A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation.

Authors:  R Graham Barr; Eugene A Berkowitz; Francesca Bigazzi; Frederick Bode; Jessica Bon; Russell P Bowler; Caroline Chiles; James D Crapo; Gerard J Criner; Jeffrey L Curtis; Chandra Dass; Asger Dirksen; Mark T Dransfield; Goutham Edula; Leif Erikkson; Adam Friedlander; Maya Galperin-Aizenberg; Warren B Gefter; David S Gierada; Philippe A Grenier; Jonathan Goldin; MeiLan K Han; Nicola A Hanania; Nadia N Hansel; Francine L Jacobson; Hans-Ulrich Kauczor; Vuokko L Kinnula; David A Lipson; David A Lynch; William MacNee; Barry J Make; A James Mamary; Howard Mann; Nathaniel Marchetti; Mario Mascalchi; Geoffrey McLennan; James R Murphy; David Naidich; Hrudaya Nath; John D Newell; Massimo Pistolesi; Elizabeth A Regan; John J Reilly; Robert Sandhaus; Joyce D Schroeder; Frank Sciurba; Saher Shaker; Amir Sharafkhaneh; Edwin K Silverman; Robert M Steiner; Charlton Strange; Nicola Sverzellati; Joseph H Tashjian; Edwin J R van Beek; Lacey Washington; George R Washko; Gloria Westney; Susan A Wood; Prescott G Woodruff
Journal:  COPD       Date:  2012-03-19       Impact factor: 2.409

4.  Chronic obstructive pulmonary disease: an overview.

Authors:  John F Devine
Journal:  Am Health Drug Benefits       Date:  2008-09

Review 5.  Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives.

Authors:  Daniel J Hassett; Michael T Borchers; Ralph J Panos
Journal:  J Microbiol       Date:  2014-03-01       Impact factor: 3.422

6.  Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes.

Authors:  Russell P Bowler; Sean Jacobson; Charmion Cruickshank; Grant J Hughes; Charlotte Siska; Daniel S Ory; Irina Petrache; Jean E Schaffer; Nichole Reisdorph; Katerina Kechris
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

7.  A ferret model of COPD-related chronic bronchitis.

Authors:  S Vamsee Raju; Hyunki Kim; Stephen A Byzek; Li Ping Tang; John E Trombley; Patricia Jackson; Lawrence Rasmussen; J Michael Wells; Emily Falk Libby; Erik Dohm; Lindy Winter; Sharon L Samuel; Kurt R Zinn; J Edwin Blalock; Trenton R Schoeb; Mark T Dransfield; Steven M Rowe
Journal:  JCI Insight       Date:  2016-09-22

8.  Clinical Features according to the Frequency of Acute Exacerbation in COPD.

Authors:  Seung Jun Lee; Seung Hun Lee; Yu Eun Kim; Yu Ji Cho; Yi Yeong Jeong; Ho Cheol Kim; Jin Hyun Kim; Jin Jong You; Chul-Ho Yoon; Jong Deog Lee; Young Sil Hwang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-04-30

9.  Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.

Authors:  Mark T Dransfield; Andrew M Wilhelm; Brian Flanagan; Clifford Courville; Sherry L Tidwell; S Vamsee Raju; Amit Gaggar; Chad Steele; Li Ping Tang; Bo Liu; Steven M Rowe
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

10.  Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation.

Authors:  Michael H Cho; George R Washko; Thomas J Hoffmann; Gerard J Criner; Eric A Hoffman; Fernando J Martinez; Nan Laird; John J Reilly; Edwin K Silverman
Journal:  Respir Res       Date:  2010-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.